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Energy metabolismThe interconnectivity between diet, gut microbiota and cell molecular responses is well known; however,
only recently has technology allowed the identiﬁcation of strains of microorganisms harbored in the gas-
trointestinal tract that may increase susceptibility to cancer. The colonic environment appears to play a
role in the development of colon cancer, which is inﬂuenced by the human metabolic lifestyle and
changes in the gut microbiome. Studying metabolic changes at the cellular level in cancer be useful for
developing novel improved preventative measures, such as screening through metabolic breath-tests
or treatment options that directly affect the metabolic pathways responsible for the carcinogenicity.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Historically unparalleled access to excessive amounts of food
and a predominantly sedentary lifestyle in modern society has re-
sulted in an increasing epidemic of ‘‘metabolic syndrome’’. Meta-
bolic syndrome is a complex of interrelated risk factors for
cardiovascular disease (stroke and cardiac infarction) and diabetes.
Risk factors include dysglycemia, high blood pressure, elevated tri-
glyceride levels, low high-density lipoprotein cholesterol levels,
and obesity. Many suggested deﬁnitions exist, but a recent consen-
sus proposed that 3 abnormal ﬁndings out of 5 would qualify a per-
son for metabolic syndrome [1]. Notably, the associations between
and clustering of these factors have been known for decades. More
recently, interest has focused on the involvement of insulin resis-
tance as a linking factor, although the pathogenesis remains un-
clear and diagnostic criteria have not been established. Central to
the understanding of metabolism and cancer is the relationship be-
tween epidemiological metabolic risk factors and diet, the relation-
ship between diet and changes in metabolism per se and how
alterations in metabolism may occur through changes in the gut
microbiome, which is also affected by dietary intake [2–6].Eventually, these external inﬂuences may have internal effects on
cellular metabolism, and the mitochondria may be key players
[7–9], in the increased susceptibility of cells to becoming cancer-
ous (Fig. 1). Recently, high-throughput sequencing of the human
microbiota inhabiting the gastrointestinal (GI) tract has demon-
strated that speciﬁc gut microbiomes are correlated with speciﬁc
metabolomic markers [10]. Furthermore, understanding the gut
microbiome, which can be altered with lifestyle changes, such as
changes in diet and body weight [11], has the potential to elucidate
the interconnectivity between these conditions and improve the
prevention, diagnosis and treatment of diseases, including cancer.
In this review, we investigate some of the current concepts in
cancer development with respect to metabolism in the human
body and within cells. In particular, we focus on the effects that
certain nutrients and metabolic alterations have on colorectal can-
cer cells. This knowledge may improve preventive measures, diag-
nosis and treatment and provide a better understanding of the
disease.2. Colorectal carcinogenesis
Colorectal cancer (CRC) is one of the most frequently occurring
forms of cancers worldwide, causing as many as 600,000 deaths
annually, and represents a high disease burden to society [12–
14]. The lifetime risk of CRC in theWestern population is estimated
Fig. 1. Altered cellular energy metabolism in cancerogenesis. Reproduced with permission from Hagland et al. in Digestive Surgery, 2013.
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274 H.R. Hagland, K. Søreide / Cancer Letters 356 (2015) 273–280to be 5–6% [15,16], with >90% of cases of sporadic or unknown ori-
gin and <10% caused by known hereditary cancer syndromes
[17,18]. Most sporadic cases (85%) present with chromosomal
instability (CIN), which results in cell aneuploidy, whereas the
remaining cases (15%) have microsatellite instability (MSI) pheno-
types [19]. MSI tumors are characterized by single nucleotide
mutations in repetitive DNA sequences found throughout the gen-
ome [20]. Affected genes include MLH, MSH2 and MSH6, which
control the DNA mismatch repair machinery [20]. Another com-
mon observation in colon cancer is the hypermethylation of CpG
islands, most often found in the promoter areas of genes. Hyper-
methylation of CpG islands affects gene transcription epigeneti-
cally. In sporadic MSI cases, hypermethylation of the promoter
regions of MLH1 is often observed and causes the nucleotide muta-
tions typical of MSI [21,22]. These tumors are characterized by
proximal location, poor differentiation, mucinous histology and
lymphocytic inﬁltration [19]. In addition, MSI tumors have a pro-
nounced susceptibility to PI3K inhibitors, suggesting that they
are particularly dependent on this pathway [23]. The localization
of a CRC tumor appears to dictate commonalities that have been
suggested as classiﬁcation markers for CRC, such as MSI, CIN and
CpG island methylation (CIMP). The macromolecular milieu in
the colon may therefore play a signiﬁcant role in the development
of these tumors, which is why lifestyle-related factors are being
heavily investigated as instigators of tumorigenesis in sporadic
CRC [24–27]. Finally, CRC may develop in an inﬂammatory back-
ground resulting from severe and chronic activity in inﬂammatory
bowel disease (Crohn’s disease or ulcerative colitis). Contrary to
the early reports of a very high cancer risk in these patients,
primarily populations with severe disease investigated in tertiary
referral centers, many later epidemiological follow-up studies havedemonstrated only a moderately increased risk of cancer develop-
ment, which is likely greater for Crohn’s disease than ulcerative
colitis [28]. However, compared with sporadic or hereditary CRC,
risk is increased, and the mechanisms appear to be different. The
involvement of microbiota in the damaged epithelium has gar-
nered interest and serves as an investigational model for inﬂam-
mation carcinogenesis. A recent overview, including proposed
molecular mechanisms, has been reported in this Journal [29]
and is beyond the scope of this review.
3. Diet, lifestyle and cancer risk
Risk factors for developing colon cancer include age, male sex,
previous colonic polyps, previous CRC and environmental factors
[19], such as diet, weight and general lifestyle. An increasing num-
ber of patients are being diagnosed with metabolic syndrome,
including obese patients and patients with type 2 diabetes, cardiac
disease and GI disorders in the Western world. High caloric intake
and reduced activity are the main contributors to the development
of these metabolic syndromes, and genetic predispositions are also
risk factors. A high body mass index (BMI) and waist circumference
are clear risk factors for CRC, although little is known about the
connection between these parameters and the different molecular
disease subsets. The epigenetically modiﬁed CIMP in CRC was
recently investigated to determine the associations between BMI
and known methylation patterns. No signiﬁcant association was
observed between high BMI and CIMP or non-CIMP status [30],
which was somewhat surprising. However, other studies have
demonstrated that childhood and adolescent height and weight
play a role; energy restriction at a young age decreased the risk
of CRC later in life [31–33]. Moreover, severe energy restriction
Fig. 2. Multidimensional, complex interplay between lifespan, exposure and outcome. Illustration of the multidimensional, complex interplay between lifespan exposures
related to eventual outcomes, which underlies the investigation of potential biomarkers or risk mediators, illustrated here by the mTOR pathway. Curr. Nutr. Rep. 2013
March;2(1):19–26.
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risk of developing a CIMP tumor [34]. Energy restriction and its
protection against cancer is not a new phenomenon, as this associ-
ation has been reported in a number of studies over the years,
although many are experimental studies performed in rodents
(for an extensive review, see [35]). Studies investigating obesity
in relation to epigenetic molecular metabolic proﬁling and cancer
risk have also been published [36]. However, it appears that the
timing of energy restriction, i.e., during childhood, adolescence or
adulthood, inﬂuences cancer prevalence [37]. The precise molecu-
lar mechanism behind this phenomenon has yet to be deﬁned,
although some candidate pathways have been suggested [38–42].
Investigation into the complex ﬁeld of molecular epidemiology
and risk assessment of the relationship between lifestyle and
exposure and the eventual outcome are challenging, as shown for
the mTOR pathway in Fig. 2. Nonetheless, increased knowledge
in this area may address whether the timing of exposure to energy
intake (be it excessive or restrictive) and the resultant BMI values
inﬂuence epigenetic changes in cancers later in life. Indeed, a
multidisciplinary and integrated research ﬁeld has been created
to better understand the biology of disease [43,44]. While meta-
bolic syndrome, insulin resistance and adiponectines serve as risk
modiﬁers for neoplasia development in obesity, other proposed
mechanisms (such as gut microbiota and bile acids) continue to
be controversial [45], as outlined in the summary model in Fig. 3.
4. GI tract microbiome and inﬂuence on colorectal cancer
A healthy human body contains at least tenfold more bacterial
cells than human cells, and the most abundant and diverse micro-
bial community resides in the intestinal tract. The GI tract harbors
the largest quantity of microbes by far, estimated at approximately
100 trillion, as much as tenfold more than all of the somatic and
germ cells in our body [46,47]. The symbiotic relationship between
the human cells and microbiota in the human body is not wellunderstood and clearly requires further investigation. An increas-
ing body of knowledge suggests that the microbiota play an impor-
tant role in ‘‘lifestyle-related illnesses’’. Several studies have
suggested that the microbiota of the GI tract is ‘‘inherited’’ and
subsequently modiﬁed throughout life by diet or exposure [48–
52]. Symbiosis in this multifaceted organ is thus crucial to main-
taining a healthy balance within the host-diet-microbiota triangle,
and accordingly, changes to any of these three factors may drive a
healthy situation into a state of disease. The ﬁrst exposure to GI
microbiota is from the mother through birth [48], whereas babies
born by cesarean delivery may experience the microbiota of the
hospital as their ﬁrst encounter to microbes [49]. The intestinal
microbiota develop in symbiosis with the cells of the GI tract,
and although the precise species and variability of existing micro-
biota are unknown, there is a general consensus that the human
intestinal ‘‘core microbiota’’ at the phylum level are composed of
Proteobacteria, Bacteroidetes, Firmicutes and Actinobacteria [53–
57]. However, identifying and understanding what makes and dis-
tinguishes ‘‘good’’ from ‘‘bad’’ bacteria and how the microbiome
may inﬂuence human health are considerable challenges.
The inﬂuence of some bacteria and viruses on cancer develop-
ment is well known. It has been estimated that approximately
20% of the global cancer burden is linked to infectious agents
[58], and two well-known examples are the induction of cervical
cancer by human papillomaviruses and of gastric cancer by Helico-
bacter pylori [58,59]. Indeed, an increasing amount of recent data
supports the hypothesis that CRC can be initiated by bacteria ‘‘driv-
ing’’ cancer development, while other ‘‘passenger’’ bacteria strains
promote the cancer [60]. Mechanisms of microbial inﬂuence on
cancer development in the intestinal tract [61–63] include the
balance of pro- and anti-inﬂammatory signals, the direct effects
of bacterial enterotoxins on mucosal cells and intracellular path-
ways and the indirect potential of bacteria in the conversion of
pro-carcinogenic dietary factors into carcinogens [64–67]. A
thorough understanding of these processes will provide directions
Fig. 3. Mechanistic summary of potential factors linked to obesity, inﬂammation and colorectal cancer. Blue arrows indicate the metabolic consequences of obesity. Black
arrows represent suspected consequences of dysbiotic microbiota. Purple arrows represent cellular events induced by obesity-related metabolic changes. Red arrows localize
these cellular events within the carcinogenic process. Green arrows represent the proposed stage of the normal epithelium-to-carcinoma sequence when the different
biological factors may start to act. Orange lines indicate some suggested potentially beneﬁcial effects of bariatric surgery. FFA, free fatty acid; IGF-1, insulin-like growth factor
1; IL, interleukin; MIF, macrophage migration inhibitory factor; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. APC, Adenomatous polyposis coli; MSI,
microsatellite instability, K-ras, Kirsten-rat sarcoma, Cox-2, cyclooxygenase-2; DCC (deleted in colorectal carcinomas), DPC4 (deleted in pancreatic carcinomas, locus 4).
Reproduced from Obesity and colorectal cancer, Bardou et al., Gut 2013;62:933–947. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
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276 H.R. Hagland, K. Søreide / Cancer Letters 356 (2015) 273–280for future research and may ultimately aid in the development of
new strategies for CRC diagnosis and prevention.
Metagenomics projects involving high-throughput/next-gener-
ation sequencing have been initiated to characterize the microbes
within the human body [68–73], in which the gut microbiome is
highly enriched for genes involved in energy production and
metabolism [47,70]. The intestinal microbe population is heteroge-
neous and composed of more than 1000 different bacterial species
[74]. The bacterial density in the large intestine is 12-fold higher
than that in the small intestine. Interestingly, there is an estimated
12-fold increase in cancer risk in the large intestine compared with
the small intestine [74]. Functional contributions of the gut micro-
biota that may inﬂuence cancer susceptibility in the broad sense
include the following [75]:
 harvesting otherwise inaccessible nutrients and/or sources of
energy from the diet (i.e., fermentation of dietary ﬁbers and
resistant starch);
 metabolizing xenobiotics, including those that are potentially
beneﬁcial and detrimental (i.e., dietary constituents, drugs,
carcinogens, etc.);
 renewing gut epithelial cells and maintaining mucosal integ-
rity; and
 affecting immune system development and activity [76].The fact that the microbiota found in the colon is enriched for
genes involved in energy production and extraction, in which car-
bohydrate metabolism is particularly overrepresented in the fam-
ily of glycoside hydrolases and polysaccharide lyases [77], begs
the question of how these particular microbiota inﬂuence colon
cell metabolism. Dietary carbohydrates, speciﬁcally starches and
ﬁber, are substrates for fermentation by microbes in the colon,
which results in short chain fatty acids (SCFAs), such as acetate,
propionate and butyrate [78]. Whereas acetate enters the periphe-
ral circulation to be metabolized by peripheral tissues, propionate
is largely taken up by the liver, and butyrate is the major energy
source for colonocytes [78]. The proximal colon contains the high-
est number of bacteria and shows the highest fermentation ratios
and highest proliferation rates, most likely because substrate avail-
ability is best [79]. The total amount of SCFAs in the proximal colon
is estimated to range from 70 to 140 mM, and the amount of SCFs
falls to 20 to 70 mM in the distal colon [80]. The production of
SCFAs is highly dependent on the substrate source and the dietary
intake of non-digestible carbohydrates in the form of starches and
ﬁber varies. The colon absorbs water, lipids and minerals from
food, and the quantity of substrates available for fermentation de-
creases from the proximal to distal side [79]. Total SCFA and regio-
nal differences in concentration are implicated in colonic diseases,
especially in cancer and GI disorders that most often occur distally
H.R. Hagland, K. Søreide / Cancer Letters 356 (2015) 273–280 277[78]. High animal protein intake and a high-fat diet are known risk
factors associated with colon cancer. Such diet is common in the
western world, whereas in Africa, where the prevalence of colon
cancer is relatively low, the staple diet consists of maize meal,
which is rich in resistant starch [81]. A study analyzing the colon
contents of native Africans, African Americans and Caucasian
Americans found that the butyrate concentration was signiﬁcantly
higher in native Africans compared with the two American groups
[82]. This supports the notion that the Western diet, which has a
higher dietary intake of animal products, may alter the gut micro-
biota and thus play a key role in carcinogenesis.
The intestinal bacteria composition is relatively stable through-
out adult life; however, the strain composition varies from person
to person [60]. The ‘‘core microbiome’’ hypothesis states that there
are many microbial functions that are genetically similar, but the
strains of bacteria may vary at the species level [53,83]. Further-
more, increasing evidence suggests that there is a correlation be-
tween the type of bacteria found in the colon and the risk of
developing colon cancer [60]. Analysis of microbes in non-tumor
sites compared with sites within tumors in the colon of CRC pa-
tients has led to the development of the ‘‘driver’’ and ‘‘passenger’’
theory of tumorigenesis, as previously mentioned [60]. The
commonly found bacterial strains at tumor sites were Fusobacte-
rium, which function as ‘‘passenger’’ bacteria. Enterotoxigenic
Bacteroides fragilis (ETBF) strains of bacteria were found at non-
tumor sites and are characterized as ‘‘driver’’ bacteria [84–86].
5. Cellular metabolism and relationship to cancer
Nearly a century ago, the German physiologist and Nobel laure-
ate Otto Warburg made the discovery that cancer cells secreted
more lactate than normal cells under aerobic conditions, indicating
higher glucose usage compared with normal cells [87]. This discov-
ery was later termed the ‘‘Warburg effect’’ and was initially be-
lieved to be caused by a hostile tumor microenvironment that
had damaged mitochondria, resulting in higher glycolysis [88,89].
This theory has later been disproven, as most tumor cells still har-
bor functionalmitochondria and use oxidative phosphorylation and
glycolysis to support cell growth [89,90]. However, the observation
of higher glucose ﬂux through cancer cells remains valid and is also
exploited in the 2-ﬂuorodeoxyglucose positron emission tomogra-
phy (2-FDG PET) scan used to identify metastasis in the clinic today.
This glucose preference and metabolic switch observed in can-
cer cells is now recognized as one of the hallmarks of cancer [91].
The increase in glycolysis is necessary to support rapid cell growth,
and pathways emerging from the breakdown of glucose include
the pentose phosphate pathway. This pathway involves the
conversion of glucose-6-phosphate and fructose-6-phosphate to
ribose-5-phosphate, which is the precursor for nucleotide biosyn-
thesis, and glyceraldehyde-3-phosphate, a precursor for the phos-
pholipids needed to build new membranes. The entire metabolic
shift is required to maintain a high proliferation rate, which is pre-
determined by the different activating mutations in oncogenes and
subsequent deactivating mutations in tumor suppressor genes.
While the basic metabolic currency is universal to all cells
(e.g., NADH, NADPH, ATP, acetyl coenzyme A, GTP), the speciﬁc
metabolic requirements are controlled by the cellular environment
and tissue function. Consequently, highly proliferative cells, such
as lymphocytes activated by an immune response, must maintain
a high carbon ﬂux to sustain the high use of energy and require
biomolecules to support the biosynthesis of new cells [92,93],
which explains why common mutations in cancers genes are
related to metabolism [94].
One of the most commonly deregulated pathways reported in
cancer cells is the phosphoinositide-3-kinase (PI3K)–AKT pathway
[95]. In CRC, theWNT/b-catenin pathway, transforming growth fac-tor beta (TGFb) and epidermal growth factor receptor (EGFR) path-
way, with its downstream targets RAS, RAF, and PI3K–AKT [96],
are oftenderegulated. All of the above-mentionedpathways interact
with cellular metabolism at some level. Perturbations in the PI3K–
AKT pathway in particular have been associated with increased gly-
colytic ﬂux and glucose dependence [97]. This increase renders cells
more resistant to conventional cancer treatments [98] but may
make them more vulnerable to other types of treatment [99,100].
Furthermore, it has become evident that many tumor suppres-
sor genes are epigenetically regulated [101,102]. This ﬁnding im-
plies that in a state of high energy availability, which is often the
case when a cell increases nutrient uptake in response to a growth
factor, these genes may be silenced by mechanisms such as meth-
ylation. When the extracellular signal that triggers a proliferation
event becomes self-autonomous, nutrient uptake and cellular en-
ergy will be maintained at a high level, causing the cell to lose the
‘‘on and off’’ epigenetic control of these tumor suppressor genes.
The longstanding idea that growth factors directly trigger genetic
events that require ATP, therefore shifting the ATP:ADP levels and
causing the cell to adapt and increase its metabolic machinery to
compensate, is under attack. This previous hypothesis is based on
the classic model of single cell eukaryotic metabolism; however,
under low nutrient availability, cells maximize the use of nutrients
for ATP production, whereas when nutrients are plentiful, cells
redirect their metabolism for growth. Thus, it has recently been
suggested that themetabolic shift is the ﬁrst event after growth fac-
tor binding and is not a result of ATP decrease. Instead, the shift is a
means to increase the supply of reduced carbon, reduced nitrogen
and NADPH for reductive biosynthetic reactions, which are critical
for themacromolecular synthesis of nucleotides, proteins and lipids
tomake new daughter cells (Ward and Thompson [90]). Supporting
this idea, seven glucose molecules are required to make sufﬁcient
NADPH for one fatty acyl molecule, whereas one glucose molecule
can produce ﬁvefold more ATP than required for this reaction to oc-
cur [103]. Although the value of ATP should not be underestimated,
NADPH is also an essential co-factor in proliferating cells [104]. If all
available glucose were funneled through glycolysis via the tricar-
boxylic acid (TCA) cycle to maximize ATP production, the produc-
tion of NADPH via the pentose phosphate pathway would be
stalled, further inhibiting the export of citrate for producing lipids.
Conversely, all of the pathways involved in generating molecules
for biomass production are dependent on high glucose ﬂux through
glycolysis, not ATP production. Furthermore, complete oxidation of
each glucose molecule would result in high ATP levels that would
induce feedback and shut down glycolysis, something that is
avoided by the recycling of ATP to ADP via lactate dehydrogenase
and lactate secretion in cancer cells [103].
These metabolic changes common in cancer cells are required
for the cells to proliferate. The pathways controlling these changes
are most often deregulated, as observed with the PI3K–AKT path-
way, and EGFR controls nutrient uptake and intracellular distribu-
tion. Our increasing understanding of how intracellular pathways
and key effector proteins orchestrate the required uncontrolled
growth of cancer cells will allow new drugs to be tested for cancer
treatment in the future.
6. The butyrate paradox
‘‘The butyrate paradox’’ refers to the opposing effects that the
metabolite butyrate has on the proliferation of normal versus
cancerous colon cells [105]. Butyrate is predominantly produced
by the colonic bacteria Clostridia clusters XIVa and IV of Firmicutes
from food residues, such as dietary ﬁber or resistant starch [81].
The oxidation of butyrate in colonocytes supplies more than 70%
of the required energy, thereby reducing glucose oxidation and
saving pyruvate and glutamine. This phenomenon is likely due to
278 H.R. Hagland, K. Søreide / Cancer Letters 356 (2015) 273–280an evolutionary adaptation based on the most available substrate
in this area. The highest butyrate oxidation occurs in the proximal
colon [80], whereas butyrate was not detectable in stool samples
after a whole gut transit time of greater than 50 h [80], likely
due to colonic uptake. Butyrate levels have also been measured
[106] by liquid chromatography–tandem mass spectrometry (LC–
MS/MS) in the lumen of mouse colons, in which decreasing buty-
rate concentrations (3.5, 0.8 and 0.5 mM) were observed in the
proximal, medial and distal segments, respectively. Butyrate is
metabolized in the mitochondria of cells via the b-oxidation path-
way in the matrix. It then enters the TCA as acetyl-CoA, which to-
gether with oxaloacetate generates citrate via citrate synthase.
Citrate can be further metabolized in the TCA cycle to generate
electrons for the electron transport chain, fueling ATP production;
in cells in which the demand for ATP is relatively low, citrate can
be exported out of the mitochondria and converted back to oxalo-
acetate and acetyl-CoA in the cytosol by ATP citrate lyase. ATP cit-
rate lyase has also been identiﬁed in the nucleus, where it is
involved in histone acetylation events via histone acetylase trans-
ferase (HAT) [101]. Acetyl-CoA is a precursor for building lipids de
novo and also is the donor of the acetyl groups found on histones
that render genes more readily accessible for transcription by
opening the heterochromatin to the more relaxed euchromatin
form. Hence, under conditions in which there is a high inﬂux of
nutrients generating metabolites, such as ATP and acetyl-CoA, such
conditions will impact gene regulation via epigenetic events, such
as phosphorylation and acetylation, respectively. Andriamihaja
et al. observed that the concentration limit for butyrate metabo-
lism was 2 mM in colon cancer cells [107]. Higher concentrations
of butyrate were not metabolized but accumulated intracellularly
in the nucleus to work directly as histone deacetylase inhibitors
(HDACs) [106,107], causing epigenetic changes that turned on
genes that regulate apoptosis rather than inducing proliferation
[106]. In both cases, histones are regulated epigenetically by acet-
ylation events, but the outcome differs according to nuclear-local-
ized ATP citrate lyase [106]. In cancer cells, in which there is a
metabolic shift towards glycolysis and glucose utilization, it is
hypothesized that increased glucose uptake and lactate secretion
[108] diminishes the utilization of oxidative phosphorylation and
the use of butyrate as a substrate [77]. Therefore, butyrate accumu-
lates in the nucleus and induces apoptosis via HDAC inhibition and
the transcription of apoptotic genes [106]. Consistent with the oxi-
dative metabolic capacity of the cells being studied, a concentra-
tion range of 0.5–1 mM butyrate corresponded with the acetyl-
CoA/HAT mechanism, whereas higher concentrations (2–5 mM)
shifted the mechanism to HDAC inhibition.
Furthermore, independent groups have demonstrated that
long-term incubation of colon cancer cell lines in culture medium
containing butyrate does not increase butyrate oxidation but does
lead to its incorporation into cellular lipids, such as phospholipids
and triacylglycerides. This effect was dependent on glucose in the
culture medium [109]. In this study, glucose was channeled into
the pentose phosphate pathway to generate NADPH, which could
be used to increase the incorporation of butyrate into lipids. Inter-
estingly, the fact that butyrate was not oxidized in the mitochon-
dria but was stored as lipid droplets in the cells is consistent
with another study that demonstrated that carnitine palmitoyl
transferase 1 (CPT1) was translocated to the nucleus in CRC tumors
while fatty acid synthase (FAS) was increased in the cytoplasm.
This action would effectively prevent the fatty acid oxidation of
stored lipids in the cytoplasm. Moreover, CPT1 in the nucleus
co-immunoprecipitated with HDACs, suggesting an interaction
between these proteins. This protein–protein interaction was not
observed in normal mucosa tissues in which CPT1 was present in
its usual form in the outer mitochondria and functioned as a long
chain fatty acid transporter for fatty acid b-oxidation [110].7. Future directions
The evidence discussed above clearly suggests that there are
links between diet and lifestyle, metabolic syndrome and obesity
and inﬂammation and the risk of cancer development. Exactly
why, how and through what mechanisms remain to be clearly elu-
cidated. However, the idea that the microbial content of the GI
tract can be altered using pre- or probiotics is being tested, and
new and improved strains of bacteria with beneﬁcial effects are
being developed for this purpose with hopes of inﬂuencing disease
course and improving health [111]. If there is a symbiotic relation-
ship between an already established tumor and its microbial cli-
mate, the notion that a change to this microclimate may also
affect the growth of the tumor is intriguing.Conﬂict of Interest
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